All In Biotech

Drug Trial Radar · NCT07797322

A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function

A Phase 1, Single-dose, Open-label Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Participants With Normal Renal Function

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Mar 1, 2027

Study completion Mar 2, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess any potential exposure increases of PKN605 in participants with reduced renal function to support decisions on participant eligibility and dosing in subsequent clinical trials of PKN605.

Conditions

  • Participants With Moderate and Severe Renal Impairment and Healthy Participants

Interventions

  • PKN605Drug

    PKN605 orally as a tablet under fasted conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary plasma PK parameters: CmaxTime frame: Up to 5 days
  2. Primary plasma PK parameters: AUClastTime frame: Up to 5 days
  3. Primary plasma PK parameters: AUCinfTime frame: Up to 5 days
  4. Secondary plasma PK parameters: TmaxTime frame: Up to 5 days
  5. Secondary plasma PK parameters: AUC0-tTime frame: Up to 5 days
  6. Secondary plasma PK parameters: T1/2Time frame: Up to 5 days
  7. Secondary plasma PK parameters: TlastTime frame: Up to 5 days
  8. Secondary plasma PK parameters: CL/FTime frame: Up to 5 days
  9. Secondary plasma PK parameters: Vz/FTime frame: Up to 5 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

  • Orlando Clinical Research Center Inc

    Orlando, Florida · Recruiting

  • Genesis Clinical Research

    Tampa, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.